Liver Arginase Antikörper
-
- Target Alle Liver Arginase (ARG1) Antikörper anzeigen
- Liver Arginase (ARG1) (Arginase, Liver (ARG1))
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser Liver Arginase Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Immunoprecipitation (IP), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Kreuzreaktivität
- Human, Maus, Ratte
- Produktmerkmale
-
Rabbit Polyclonal antibody to Arginase 1 (arginase, liver)
Arginase 1 antibody - Aufreinigung
- Purified by antigen-affinity chromatography.
- Güteklasse
- KO Validated
- Immunogen
- Full length human Arginase 1 Recombinant protein.
- Isotyp
- IgG
-
-
- Applikationshinweise
- WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IHC-Fr: 1:100-1:1000. FACS: 1:50-1:200. IP: 1:100-1:1000. ELISA: 1:1000-1:10000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
- Kommentare
-
Positive Control: HepG2
Validation: KO/KD, Orthogonal
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.26 mg/mL
- Buffer
- 1XPBS pH 7, 1 % BSA, 20 % Glycerol, 0.025 % ProClin 300
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
-
-
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors." in: Molecular therapy oncolytics, Vol. 17, pp. 431-447, (2020) (PubMed).
: "Optimizing Mannose "Click" Conjugation to Polymeric Nanoparticles for Targeted siRNA Delivery to Human and Murine Macrophages." in: ACS omega, Vol. 4, Issue 16, pp. 16756-16767, (2019) (PubMed).
: "Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice." in: Nature medicine, Vol. 24, Issue 9, pp. 1418-1429, (2019) (PubMed).
: "Metabolic regulation of gene expression by histone lactylation." in: Nature, Vol. 574, Issue 7779, pp. 575-580, (2019) (PubMed).
: "IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis." in: BMC microbiology, Vol. 17, Issue 1, pp. 185, (2018) (PubMed).
: "Identification of different macrophage subpopulations with distinct activities in a mouse model of oxygen-induced retinopathy." in: International journal of molecular medicine, Vol. 40, Issue 2, pp. 281-292, (2018) (PubMed).
: "Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory ..." in: Journal of neuroinflammation, Vol. 14, Issue 1, pp. 36, (2018) (PubMed).
: "The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma." in: Oncotarget, Vol. 7, Issue 41, pp. 67333-67346, (2018) (PubMed).
: "Metabolic origins of spatial organization in the tumor microenvironment." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Issue 11, pp. 2934-2939, (2017) (PubMed).
: "Tissue matrix arrays for high-throughput screening and systems analysis of cell function." in: Nature methods, Vol. 12, Issue 12, pp. 1197-204, (2016) (PubMed).
: "Anti-Inflammatory Immune Skewing Is Atheroprotective: Apoe-/-Fc?RIIb-/- Mice Develop Fibrous Carotid Plaques." in: Journal of the American Heart Association, Vol. 3, Issue 6, (2014) (PubMed).
: "
-
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors." in: Molecular therapy oncolytics, Vol. 17, pp. 431-447, (2020) (PubMed).
-
- Target
- Liver Arginase (ARG1) (Arginase, Liver (ARG1))
- Andere Bezeichnung
- arginase 1 (ARG1 Produkte)
- Synonyme
- SI:zC146F4.4 (novel protein with NUDIX domain) antikoerper, si:ch211-146f4.3 antikoerper, argi1 antikoerper, AI antikoerper, AI256583 antikoerper, Arg-1 antikoerper, PGIF antikoerper, arginase 1 antikoerper, arginase antikoerper, Arginase-1 antikoerper, arginase, liver antikoerper, L-arginase antikoerper, arg1 antikoerper, PGTG_16455 antikoerper, argi1 antikoerper, ARG1 antikoerper, Arg1 antikoerper
- Hintergrund
-
Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by this gene, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia.
Cellular Localization: Cytoplasm - Molekulargewicht
- 35 kDa
- Gen-ID
- 383
- UniProt
- P05089
- Pathways
- Cellular Response to Molecule of Bacterial Origin
-